Clinical Trial Update: Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial is evaluating BMN 333 versus Vosoritide to assess efficacy and safety in children with achondroplasia; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achondroplasia

Drugs mentioned

• BMN 333
• Vosoritide (vosoritide)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Achondroplasia | Phase 2, Phase 3 | Status: RECRUITING